Biofrontera Inc. (BFRIW) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Woburn, DE, United States. El CEO actual es Hermann Luebbert.
BFRIW tiene fecha de IPO 2021-10-29, 92 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $349.45K.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
